Leerink Partnrs Has Positive Outlook for ACAD Q4 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Analysts at Leerink Partnrs boosted their Q4 2025 EPS estimates for shares of ACADIA Pharmaceuticals in a research note issued to investors on Wednesday, November 5th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings of $0.11 per share for the quarter, up from their prior forecast of $0.09. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ FY2026 earnings at $0.60 EPS, FY2027 earnings at $0.85 EPS, FY2028 earnings at $1.15 EPS and FY2029 earnings at $0.95 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.28. The business had revenue of $278.63 million for the quarter, compared to analyst estimates of $276.52 million. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The firm’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.20 earnings per share. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS.

Several other research firms have also recently weighed in on ACAD. Weiss Ratings reiterated a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research note on Tuesday, October 14th. JPMorgan Chase & Co. lowered their target price on shares of ACADIA Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Monday, September 29th. UBS Group boosted their price objective on ACADIA Pharmaceuticals from $36.00 to $39.00 and gave the stock a “buy” rating in a research note on Tuesday, September 9th. Wall Street Zen downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, September 5th. Finally, Deutsche Bank Aktiengesellschaft set a $29.00 target price on ACADIA Pharmaceuticals in a research note on Thursday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.94.

ACADIA Pharmaceuticals Price Performance

ACAD stock traded up $0.16 on Friday, reaching $21.81. 147,609 shares of the company were exchanged, compared to its average volume of 2,152,113. ACADIA Pharmaceuticals has a 12 month low of $13.40 and a 12 month high of $26.65. The stock’s fifty day moving average price is $22.69 and its 200 day moving average price is $21.84. The firm has a market capitalization of $3.68 billion, a PE ratio of 16.37, a PEG ratio of 7.90 and a beta of 0.80.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several institutional investors have recently made changes to their positions in ACAD. Geneos Wealth Management Inc. raised its holdings in ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 756 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of ACADIA Pharmaceuticals by 107.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 885 shares in the last quarter. USA Financial Formulas bought a new stake in shares of ACADIA Pharmaceuticals during the 3rd quarter worth approximately $41,000. Picton Mahoney Asset Management acquired a new stake in shares of ACADIA Pharmaceuticals during the 1st quarter worth approximately $32,000. Finally, Banque Transatlantique SA bought a new position in ACADIA Pharmaceuticals in the first quarter valued at approximately $31,000. 96.71% of the stock is currently owned by institutional investors.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, Director Elizabeth A. Garofalo sold 1,600 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $25.98, for a total value of $41,568.00. Following the transaction, the director directly owned 25,382 shares of the company’s stock, valued at $659,424.36. This represents a 5.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Mark C. Schneyer sold 3,498 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, September 15th. The stock was sold at an average price of $23.65, for a total value of $82,727.70. Following the sale, the executive vice president directly owned 43,447 shares of the company’s stock, valued at $1,027,521.55. This represents a 7.45% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 27,098 shares of company stock valued at $678,256. 26.50% of the stock is currently owned by insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.